Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer
Journal of Clinical Oncology · 10.08.2025 · 43 (23) · 2572-2582
DOI: 10.1200/jco-24-01580 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.08.2025. Verfasst von Dan P Zandberg und 13 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, Pittsburgh, PA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Chemoradiotherapy, Head and Neck Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NIDCR NIH HHS.
Abstract (Originalsprache)
PURPOSE The optimal timing of pembrolizumab with chemoradiation (CRT) in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) is unknown. Patients and Methods Our phase II trial randomly assigned patients 1:1 to concurrent pembrolizumab (200 mg once every 3 weeks × 8) starting 1 week before CRT (cisplatin 40 mg/m 2 once weekly + radiation 70 Gy) versus sequential pembrolizumab starting 2 weeks after CRT. Human papillomavirus (HPV)+ (>10 pack-years or T4 or N3) and HPV(–) LA HNSCC were included, stratified by HPV and N stage. In our pick-the-winner design, if both arms met the trivariate primary end point (1-year locoregional failure
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- UPMC Hillman Cancer Center, Pittsburgh, PA.
- Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA.
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA.
- Department of Radiation Oncology, West Virginia University, Morgantown, WV.
- UPMC Hillman Cancer Center Bioinformatics Core, Pittsburgh, PA.
- Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA.
ORCID-Profile: Dan P Zandberg, Lazar Vujanovic, Brian P Isett, Riyue Bao, James Ohr, Raja R Seethala, Robert L Ferris, Julie E Bauman
Förderung
- NCI NIH HHS
- NIH HHS
- NIDCR NIH HHS
Zitieren
APA
Zandberg, D. P., Vujanovic, L., Clump, D. A., Isett, B. P., Wang, H., Sica, G., Bao, R., Li, H., Ohr, J., Skinner, H. D., Seethala, R. R., Chiosea, S. I., Ferris, R. L., & Bauman, J. E. (2025). Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology, 43(23), 2572-2582. https://doi.org/10.1200/jco-24-01580
Vancouver
Zandberg DP, Vujanovic L, Clump DA, Isett BP, Wang H, Sica G, et al. Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology. 2025;43(23):2572-2582. doi:10.1200/jco-24-01580
BibTeX
@article{Zandberg2025,
author = {Zandberg, Dan P and Vujanovic, Lazar and Clump, David A and Isett, Brian P and Wang, Hong and Sica, Gabriel and Bao, Riyue and Li, Housayin and Ohr, James and Skinner, Heath D and Seethala, Raja R and Chiosea, Simion I and Ferris, Robert L and Bauman, Julie E},
title = {Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {23},
pages = {2572--2582},
doi = {10.1200/jco-24-01580}
}
EUVIMED